Stockscreener 앱 받기
18.76
2.04%
-0.39
Dianthus Therapeutics Inc 주식(DNTH)의 최신 뉴스
Can trapped investors hope for a rebound in Dianthus Therapeutics Inc.Swing Trade Timing with Daily Forecast - Newser
Can you recover from losses in Dianthus Therapeutics Inc.Daily Entry Opportunity Forecasting Tool - Newser
How institutional ownership impacts Dianthus Therapeutics Inc. stockDaily Profit Watch With Forecast Confidence - Newser
Will earnings trigger a reversal in Dianthus Therapeutics Inc.Predictable Income Summary for Long-Term Trades - Newser
Dianthus Therapeutics (DNTH) to Release Earnings on Thursday - MarketBeat
Relative strength of Dianthus Therapeutics Inc. in sector analysisHigh Yield Signals with Entry Timing - Newser
Custom watchlist performance reports with Dianthus Therapeutics Inc.High Return Idea With Technical Filter - Newser
Real time breakdown of Dianthus Therapeutics Inc. stock performanceQuarterly Investment Outlook and Key Summary - Newser
Brokerages Set Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Target Price at $53.00 - MarketBeat
Why Dianthus Therapeutics Inc. stock attracts strong analyst attentionFree Accurate Buy Point for Momentum Stocks - Newser
What earnings revisions data tells us about Dianthus Therapeutics Inc.Buy Strategy with Smart Exit Timing - Newser
What makes Dianthus Therapeutics Inc. stock price move sharplyCapital Secure Pattern Signal Analysis Sheet - Newser
Has Dianthus Therapeutics Inc. formed a bullish divergenceFree Expert Verified Stock Trade Ideas - Newser
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Receives Consensus Recommendation of “Buy” from Analysts - Defense World
Dianthus Therapeutics Inc. stock trend forecastFree Sector Rotation Based Trading Opportunities - Newser
Is Dianthus Therapeutics Inc. still worth holding after the dipFree Reliable Investment Entry Point Signals - Newser
Dianthus Therapeutics Reports Q2 2025 Financial Results - TipRanks
Dianthus Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Promising Outlook for Dianthus Therapeutics: Buy Rating on Claseprubart’s Potential in gMG - TipRanks
Dianthus Therapeutics: Promising Prospects with DNTH103 and Strong Financial Position Support Buy Rating - TipRanks
Dianthus Therapeutics, Inc. (DNTH) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q2 Financial Results - The Manila Times
Dianthus Therapeutics Nears Critical Phase 2 Trial Results: $309M Cash Runway Powers Multiple Clinical Programs - Stock Titan
Earnings Preview: Dianthus Therapeutics, Inc. (DNTH) Q2 Earnings Expected to Decline - Yahoo Finance
Dianthus Therapeutics (DNTH) Expected to Announce Earnings on Thursday - Defense World
Is Dianthus Therapeutics Inc. stock poised for growthFree Chart Alert System With Entry Targets - Newser
Dianthus Therapeutics Inc. stock trendline breakdownFree Triple Digit Return Stock Predictions - Newser
How moving averages guide Dianthus Therapeutics Inc. tradingDeep Learning Stock Forecast for Investors - Newser
Should I hold or sell Dianthus Therapeutics Inc. stock in 2025Discover stocks with strong growth potential - Jammu Links News
What drives Dianthus Therapeutics Inc. stock priceRapid-fire capital growth - Jammu Links News
How institutional ownership impacts Sionna Therapeutics Inc. stockFree Short Term Trading Opportunity Watch - Newser
What are the technical indicators suggesting about Dianthus Therapeutics Inc.Remarkable growth - Jammu Links News
0.24%
3.39%
자본화:
|
볼륨(24시간):